Last reviewed · How we verify
rPhleum
At a glance
| Generic name | rPhleum |
|---|---|
| Also known as | Specific Immunotherapy |
| Sponsor | Allergopharma GmbH & Co. KG |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- 2nd Pivotal Study rPhleum - Adults and Adolescents With Rhinoconjunctivitis +/-Controlled Asthma (PHASE3)
- Dose-Response-Study With a Recombinant Cocktail of Phleum (rPhleum) Allergens (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- rPhleum CI brief — competitive landscape report
- rPhleum updates RSS · CI watch RSS
- Allergopharma GmbH & Co. KG portfolio CI